Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem-cell disorders that result in cytopenias and the risk of progression to acute myeloid leukemia (AML). Although there are entrenched options to manage anemia in lower-risk (e.g., erythropoiesis-stimulating agents) and higher-risk (e.g., hypomethylating agents) patients, there is a significant gap in treatment for patients who are refractory to the first-line standards of care. The MDS pipeline is robust, and several projected market entrants are poised to penetrate subpopulations of the lower-risk and higher-risk MDS patients. Although the development of novel agents for higher-risk MDS patients has been particularly challenging, interviewed experts express enthusiasm for the clinical potential of several agents that are approved or marketed for AML, particularly those that target specific genetic populations.
- What role(s) will Bristol Myers Squibb(BMS) /Acceleron’s luspatercept (ACE-536) have in the management of MDS patients?
- What is the commercial outlook for BMS’oral azacitidine (CC-486)?
- Which emerging therapies are most likely to have an impact on the MDS therapy market in 2029 (e.g., AbbVie/Genentech’s Venclexta, Takeda’s Pevonedistat, BMS/Agios Pharmaceuticals’ Idhifa, Jazz Pharmaceuticals’ Vyxeos)? Which early-phase agents intrigue interviewed experts?
- How will the size of the MDS population change through 2029?
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Myelodysplastic Syndromes - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Rachit Singhal; Ullas Ulahannan
Nuno T. Antunes, Ph.D., is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy.
Nuno holds a Ph.D. in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a D.V.M. degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.
Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.
He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.